Sanford C. Bernstein Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €52.00 Price Target

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €52.00 ($60.47) price target by stock analysts at Sanford C. Bernstein in a research note issued on Tuesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Sanford C. Bernstein’s target price points to a potential upside of 7.14% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. DZ Bank reiterated a “buy” rating on shares of Fresenius SE & Co KGaA in a research report on Monday, November 4th. JPMorgan Chase & Co. set a €59.40 ($69.07) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, November 5th. Barclays set a €51.00 ($59.30) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Friday, October 18th. Jefferies Financial Group set a €43.00 ($50.00) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Tuesday, October 29th. Finally, Berenberg Bank set a €74.80 ($86.98) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, October 29th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Fresenius SE & Co KGaA presently has an average rating of “Buy” and a consensus target price of €56.69 ($65.92).

FRE stock opened at €48.54 ($56.44) on Tuesday. The firm has a 50 day moving average of €44.20 and a 200-day moving average of €45.92. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: What is a balanced fund?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.